Trade Nektar Therapeutics - NKTR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0160 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.017 |
| Open | 1.027 |
| 1-Year Change | 111.53% |
| Day's Range | 0.997 - 1.027 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 18, 2024 | 1.0170 | -0.0400 | -3.78% | 1.0570 | 1.0770 | 1.0070 |
| Nov 15, 2024 | 1.0570 | -0.1100 | -9.43% | 1.1670 | 1.1870 | 1.0370 |
| Nov 14, 2024 | 1.1670 | -0.1200 | -9.32% | 1.2870 | 1.2870 | 1.1570 |
| Nov 13, 2024 | 1.2770 | -0.0200 | -1.54% | 1.2970 | 1.3570 | 1.2770 |
| Nov 12, 2024 | 1.3070 | -0.0500 | -3.68% | 1.3570 | 1.3670 | 1.2970 |
| Nov 11, 2024 | 1.3570 | -0.0300 | -2.16% | 1.3870 | 1.3970 | 1.3470 |
| Nov 8, 2024 | 1.3870 | 0.0200 | 1.46% | 1.3670 | 1.4170 | 1.3570 |
| Nov 7, 2024 | 1.3670 | -0.0200 | -1.44% | 1.3870 | 1.3870 | 1.3170 |
| Nov 6, 2024 | 1.3770 | 0.0100 | 0.73% | 1.3670 | 1.4670 | 1.3570 |
| Nov 5, 2024 | 1.3770 | 0.0500 | 3.77% | 1.3270 | 1.3970 | 1.3270 |
| Nov 4, 2024 | 1.3270 | -0.0700 | -5.01% | 1.3970 | 1.4570 | 1.2570 |
| Nov 1, 2024 | 1.2170 | 0.0200 | 1.67% | 1.1970 | 1.2570 | 1.1970 |
| Oct 31, 2024 | 1.1870 | -0.0100 | -0.84% | 1.1970 | 1.2370 | 1.1870 |
| Oct 30, 2024 | 1.2470 | -0.0300 | -2.35% | 1.2770 | 1.2870 | 1.2270 |
| Oct 29, 2024 | 1.2570 | -0.0900 | -6.68% | 1.3470 | 1.3670 | 1.2470 |
| Oct 28, 2024 | 1.3570 | 0.0500 | 3.83% | 1.3070 | 1.3870 | 1.3070 |
| Oct 25, 2024 | 1.3170 | -0.0300 | -2.23% | 1.3470 | 1.3670 | 1.2970 |
| Oct 24, 2024 | 1.3470 | -0.0200 | -1.46% | 1.3670 | 1.4070 | 1.3270 |
| Oct 23, 2024 | 1.3970 | -0.0200 | -1.41% | 1.4170 | 1.4570 | 1.3670 |
| Oct 22, 2024 | 1.4270 | 0.0300 | 2.15% | 1.3970 | 1.4370 | 1.3870 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Nektar Company profile
About Nektar Therapeutics
Nektar Therapeutics is a research-based biopharmaceutical company, which is focused on discovering and developing medicines in areas of unmet medical need. The Company's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Nektar Therapeutics revenues decreased 33% to $101.9M. Net loss increased 18% to $523.8M. Revenues reflect United States segment decrease of 84% to $10.1M. Higher net loss reflects Non-cash interest expense on liabilities increase of 56% to $47.3M (expense), Interest income and other income (expens decrease of 86% to $2.6M (income).
Equity composition
Common Stock $.0001 Par, 04/11, 300M auth., 114,073,353 issd.Insiders own 0.39% . IPO: 5/94,2.15M shares @ $7.50 by Lehman Brothers. PO 12/97, 1.725Mshares @ $24.875 by Lehman Brothers. *NOTE: 2/97, 1.8M shsissued in private placement @ $18/shs. 8/00, 2-for-1 stock split. Sr B Conv. Pfd. $0.0001 Par, 0 o/s.
| Industry: | Pharmaceuticals (NEC) |
455 Mission Bay Boulevard South
SAN FRANCISCO
CALIFORNIA 94158
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com